Navigation Links
Arthrosurface Continues to Expand into Fast Growing Shoulder Market
Date:9/28/2011

FRANKLIN, Mass., Sept. 28, 2011 /PRNewswire/ -- Arthrosurface, Inc. (www.arthrosurface.com), the developer of less-invasive joint resurfacing systems, announced that a total shoulder resurfacing procedure has been performed without removing the humeral head using its new HemiCAPGRS Glenoid combined with its existing HemiCAP Humeral implant.  Shoulder arthroplasty is the third largest and fastest growing market in orthopaedics with over 25,000 procedures performed annually.  This market is forecasted to grow to nearly 60,000 procedures by 2020.  Arthrosurface's demographic is the active baby boomer that desires pain relief and function in combination with joint preservation.

"Standard shoulder replacement involves removing the humeral head which has a negative cascading effect as it forces surgeons to make a series of compromises.  Once the head is removed, restoring normal biomechanics becomes difficult as the surgeon loses reference to the anatomy.  Typically with shoulder replacements, four adjustments are needed in order to position the humeral implant at the right location; head height, neck-shaft angle and retroversion.  These, along with proper placement of the stem, to recreate the normal head offset, are critical to restoring the damaged anatomy," said John Macy, MD.

Anatomical research shows that the humeral head has an egg-shaped geometry yet existing shoulder implants are ball-shaped.  Furthermore there is research to show that the inherent mismatch between implant and anatomy can lead to loss of motion and wear.  Using its patented 3D articular surface mapping technology, Arthrosurface can map the two diameters of the humeral head and match the shape with one of its HemiCAP® implants.  "Being able to perform a stemless total shoulder resurfacing and the ability to determine and match both diameters is critical to reproducing proper biomechanics in the joint," continued Dr. Macy.

Arthrosurface reports that it is the only company to offer a full range of humeral head resurfacing implants so that surgeons can match both the size of the defect and the anatomical curves of the patients' humeral head.  With the introduction of the HemiCAPGRS Glenoid, surgeons are now able to resurface both cartilage surfaces and still respect the patients' existing anatomy.


Arthrosurface offers unique resurfacing implants designed to adhere to anatomical principles and to avoid typical patient-implant mismatches currently used in traditional orthopaedics.  "No radiographic imaging nor robotic technology can match the ability and accuracy of a surgeon that can map a patients' articular surface in 3D under direct observation and at the time of surgery when using the HemiCAP® system," said co-founder and designer, Steve Ek.






'/>"/>
SOURCE Arthrosurface, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arthrosurface® Hits the 20,000 Implant Milestone
2. 2nd Day of Testimony: Mainor Eglet Attorney Continues Questioning Teva Pharmaceuticals Vice President
3. Molecular Devices Continues to Lead the Way in Quality Control and Validation Compliance With a New ISO/IEC 17025 Accreditation
4. World Micro Strategic Business Ramp-Up Continues
5. Swedish Robotic-Assisted Surgical Program Grows, Continues to Gain Momentum
6. Texas Independent Drugstore Lobby (Continues) Putting Profits Ahead of Patients
7. e-MDs Continues Track Record of Employee and Revenue Growth
8. Ameritox® Continues to Advance Industry Leadership
9. W. L. Gore & Associates Continues Its Tradition as One of Nations Best Workplaces
10. Hotspur Technologies Continues to Bring Innovations to Peripheral Vascular Market
11. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... ... they are seeking public support to bring their novel lifesaving device for the ... device packed with medical-grade sensors, specially designed to read a child’s vital signs, ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As ... use of this type of healthcare model in the diagnosis and treatment of ...
(Date:4/24/2017)... Montclair, NJ (PRWEB) , ... April 24, 2017 , ... ... International Plaza Hotel, 4200 Jim Walter Blvd, for an educational and exciting 2-day program. ... all of our staff hearing this before they approach patients” about the course entitled ...
(Date:4/24/2017)... ... ... “Learning to Use Your SPIRITUAL COMPASS To Navigate Life Issues”: a guide to ... Navigate Life Issues” is the creation of published author, Rachel Jamerson, writer of 25 ... CONTACT USA, and former member of the American Association of Christian Counselors. Rachel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical ... for the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed ... product advances towards regulatory and clinical phases. , "This is another important step ...
Breaking Medicine News(10 mins):